![FDA issues approval for new Alzheimer's drug Kisunla; Down syndrome community is optimistic 1 kisunla](https://lumindidsc.org/wp-content/uploads/2024/07/kisunla-402x403.png)
FDA issues approval for Kisunla, new Alzheimer's drug; Down syndrome community optimistic On Tuesday, July 2, the U.S. Food and Drug Administration (FDA) announced the approval of Kisunla (donanemab), an…
![Down syndrome population will see a clinical trial of new Alzheimer’s drug 2 Alzheimer's disease in people with Down syndrome](https://lumindidsc.org/wp-content/uploads/2022/07/Researchers-brain-600x403.jpeg)
Major pharmaceutical company announces Down syndrome population will see a clinical trial of new Alzheimer’s drug People with Down syndrome will be invited to participate in a clinical trial of…
![Down syndrome collaborators now published in Alzheimer's and Dementia 3 prescription](https://lumindidsc.org/wp-content/uploads/2024/03/prescription-600x403.png)
“Adapting prescribing criteria for amyloid‐targeted antibodies for adults with Down syndrome” published in the journal of the Alzheimer’s Association Drawing attention to policies currently preventing people with intellectual disabilities from…
![LuMind IDSC statement on FDA Advisory Committee for promising Alzheimer's drug, donanemab 4 Feb2018 AlzheimersInDs 637297080437914151 o6UI7E](https://lumindidsc.org/wp-content/uploads/2019/10/Feb2018_AlzheimersInDs_637297080437914151-o6UI7E.gif)
LuMind IDSC is encouraged by today’s news that the U.S. Food and Drug Administration (FDA) is requesting more time and information before making a decision on the status of donanemab,…
![Study: Medicare, Medicaid, and Dual Enrollment for Adults with Intellectual and Developmental Disabilities. 5 MedicareInsuranceKit](https://lumindidsc.org/wp-content/uploads/2024/01/MedicareInsuranceKit-600x403.png)
Medicare, Medicaid and Dual Enrollment for Adults with IDD Boston University School of Public Health recently published an article in Health Services Research Journal entitled Medicare, Medicaid, and Dual Enrollment…
![Reuters Article: Barriers to Latest Alzheimer's Treatments for Down Syndrome Community 6 reuters logo](https://lumindidsc.org/wp-content/uploads/2023/11/reuters-logo-600x403.png)
Hampus Hillerstrom, CEO of LuMind IDSC Foundation and father to a child with Down syndrome, knows about the barriers people with Down syndrome face in accessing the latest Alzheimer's treatments.…
![Boston Globe OpEd People with Down Syndrome Now Left Out of Treatment 7 globe opinion](https://lumindidsc.org/wp-content/uploads/2023/09/globe-opinion-600x285.png)
LuMind IDSC and The Arc of Northeast collaborated on an OpEd that was recently published in The Boston Globe. Authors Hampus Hillerstrom and Jo Ann Simons are leaders of their…
![Study: Use of Medicaid by Adults with Down Syndrome 8 Image of Medicaid insurance card](https://lumindidsc.org/wp-content/uploads/2023/09/Medicaid-Insurance-600x403.png)
Medicaid Enrollment and Service Use Among Adults with Down Syndrome September 16, 2023 In a recently published study in the Journal of American Medical Association (JAMA) Health Studies it was…
![Key updates on Down syndrome community access to new Alzheimer’s drugs 9 statement header](https://lumindidsc.org/wp-content/uploads/2023/07/statement-header-600x403.png)
Five takeaways for the Down syndrome community: Updates on accessing the new Alzheimer’s drugsLuMind IDSC is working on many levels to break down the barriers that currently prevent people with…
![LuMind IDSC statement on FDA approval of Leqembi 10 leqembi](https://lumindidsc.org/wp-content/uploads/2023/07/leqembi-580x403.png)
LuMind IDSC issues statement following FDA full approval of Leqembi™ to treat early-stage Alzheimer’s disease July 7, 2023 In a groundbreaking decision that signals new hope for people with Alzheimer’s…
![MapHabit Study: Assistive Technology Has Positive Outcomes for Children with Down Syndrome 11 MapHabit Post 1.1](https://lumindidsc.org/wp-content/uploads/2023/06/MapHabit_Post_1.1-600x403.png)
Study Finds Assistive Technology Has Positive Outcomes for Children with Down Syndrome and Their Caregivers In partnership with the LuMind IDSC Foundation (LuMind IDSC), MapHabit, a neuroscience-based assistive technology (AT)…
![Expert panel addresses inequitable access to Alzheimer’s drugs for adults with Down syndrome 12 Eligibility Criteria header 1](https://lumindidsc.org/wp-content/uploads/2023/06/Eligibility-Criteria-header-1-600x403.png)
Seeking to rectify existing federal and state policies which prevent people with intellectual disabilities from accessing new therapies for Alzheimer’s disease, a group of international experts are calling for modification…
![LuMind IDSC Statement re: Donanemab Phase 3 Results 13 Brain research](https://lumindidsc.org/wp-content/uploads/2022/09/Brain-research-600x403.jpeg)
Pharmaceutical company Eli Lilly today announced results of a phase III clinical trial that proves their anti-amyloid drug, donanemab, significantly slowed cognitive and functional decline in people with early symptomatic…
![Important progress in the treatment of sleep apnea and Down syndrome 14 Sleep Apnea and Down Syndrome, LuMind IDSC Foundation](https://lumindidsc.org/wp-content/uploads/2022/03/Sleep_apnea_thumbnail_637835515606706500-7dEj44-600x403.jpeg)
At the end of March, the US Food & Drug Administration approved Inspire’s Hypoglossal Nerve Stimulator for children with Down Syndrome and significant sleep apnea who are 13 years and…
![Fierce Biotech article highlights dearth of inclusion in Alzheimer's research 15 fierce biotech head](https://lumindidsc.org/wp-content/uploads/2023/03/fierce-biotech-head-600x403.png)
"Alzheimer's meds are here. But for the Down syndrome community, it's still the 1980s" by Annalee Armstrong, Fierce Biotech An important article from industry publication Fierce Biotech highlights the lack…
![With support from Lilly, LuMind IDSC launches key research and awareness activities to advance Down syndrome research 16 Tau Tangles in Down syndrome related Alzheimer's disease](https://lumindidsc.org/wp-content/uploads/2022/08/Amyloid-plaques.jpeg)
2/22/2023 (Burlington, MA) – Today the LuMind IDSC Foundation, a leading national Down syndrome research organization, announced a new collaboration with Eli Lilly and Company (Lilly) aimed at accelerating research…
![Results from "Challenges of Caregiving" Survey Published in Research Journal 17 strong man carries mom](https://lumindidsc.org/wp-content/uploads/2023/01/strong_man_carries_mom-600x403.png)
The LuMind IDSC community and caregivers across the U.S. participated in “Challenges of Caregiving,” an online survey of caregiver perspectives on a range of topics that are important to the…
![New steps forward in treating Alzheimer's disease with lecanemab: Clinical trial reveals clear efficacy in removing brain plaque 18 AdobeStock 439291670](https://lumindidsc.org/wp-content/uploads/2022/02/AdobeStock_439291670-600x403.jpeg)
At an Alzheimer’s disease research conference last week, new clinical trial data was presented for an antibody drug candidate called lecanemab. (Read more about the development of lecanemab here.) An…
![Report of the Neuroatypical Conditions Expert Consultative Panel 19 OBI DSMSE stopwatch](https://lumindidsc.org/wp-content/uploads/2022/03/OBI-DSMSE-stopwatch.png)
innovation Detection of any cognitive impairment as part of the Affordable Care Act’s annual wellness visit in primary or other health care settings for adults with pre-existing neuroatypical or neurodivergent…
![Report of the Neuroatypical Conditions Expert Consultative Panel 20 bg](https://lumindidsc.org/wp-content/uploads/2022/02/bg-600x403.png)
Detection of any cognitive impairment as part of the Affordable Care Act’s annual wellness visit in primary or other health care settings for adults with pre-existing neuroatypical or neurodivergent conditions…
![Results From T21RS's COVID-19 International Survey on Vaccination of Individuals With DS 21 bg](https://lumindidsc.org/wp-content/uploads/2022/02/bg-600x403.png)
In a study led by the LuMind IDSC Foundation, the T21RS COVID-19 Initiative launched an international survey to obtain information on the safety and efficacy of COVID-19 vaccines for individuals…
![Five Recent Down Syndrome Research Data Articles to Stay Up to Date 22 bg](https://lumindidsc.org/wp-content/uploads/2022/02/bg-600x403.png)
Recently, two institutions in the Down Syndrome Clinical Trials Network (DS-CTN) published five studies about Down syndrome-related health and wellness, ranging from infectious diseases to mental health, skills, and independence. This new…
![LuMind IDSC Statement on CMS Proposed Coverage for Anti-Amyloid AD Drugs 23 bg](https://lumindidsc.org/wp-content/uploads/2022/02/bg-600x403.png)
During the past year, LuMind IDSC remained cautiously optimistic about treatment possibilities that the development of new drugs for Alzheimer’s disease may bring to the Down syndrome community. Because people…
![LuMind IDSC and Dr. Nicole White Publish “Parental Perspectives on Research for Down Syndrome” 24 bg](https://lumindidsc.org/wp-content/uploads/2022/02/bg-600x403.png)
Dr. Nicole White, Hampus Hillerstrom, LuMind IDSC and a team of experts, recently published an article in the Journal of Applied Research in Intellectual Disabilities, that delves into the intricacies of…
![LuMind IDSC and Team of Experts Publish Article on Aging With DS and the Future of Research 25 bg](https://lumindidsc.org/wp-content/uploads/2022/02/bg-600x403.png)
Dr. James Hendrix, LuMind IDSC's Chief Scientific Officer, along with a team of Down syndrome experts recently published an article in the Journal of Clinical Medicine, as part of the special issue…